RT Journal Article SR Electronic T1 Selection of chemotherapy for patients with advanced non–small cell lung cancer JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP S46 OP S50 DO 10.3949/ccjm.78.s2.10 VO 79 IS 5 e-suppl 1 A1 Nathan A. Pennell YR 2012 UL http://www.ccjm.org/content/79/5_e-suppl_1/S46.abstract AB Chemotherapy remains the first-line treatment for most patients with stage IV non–small cell lung cancer (NSCLC), but optimal regimens are now defined by histology. Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. Maintenance therapy is emerging as a treatment strategy for patients who do not progress after four cycles of first-line chemotherapy. In the maintenance setting, pemetrexed and erlotinib significantly prolong overall survival compared with placebo after the completion of first-line chemotherapy.